Nuo Therapeutics, Inc.·4

Jun 5, 6:34 PM ET

JORDEN DAVID EMERSON 4

4 · Nuo Therapeutics, Inc. · Filed Jun 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Nuo Therapeutics (AURX) CEO/CFO David Jorden Receives 13,245 Shares

What Happened JORDEN DAVID EMERSON (listed in the filing), who serves as CEO/CFO and a director of Nuo Therapeutics, received an award/acquisition of 13,245 shares on 2026-06-05. The reported weighted-average price for the shares is $1.10, for a total reported value of $14,506. This transaction is an acquisition/award (code A) rather than a sale.

Key Details

  • Transaction date: 2026-06-05
  • Transaction type: Award/Grant/Other acquisition (Code A)
  • Shares acquired: 13,245 shares
  • Reported weighted-average price: $1.10; actual trades ranged from $1.042 to $1.15 per share (footnote F1)
  • Reported total value: $14,506
  • Shares owned after the transaction: Not specified in the provided Form 4 excerpt
  • Timeliness: Filing date equals transaction date (2026-06-05), so the Form 4 appears timely
  • Footnote F1: Price is a weighted average across multiple transactions; the reporting person offers to provide a breakdown of purchases by price upon request.

Context This was an acquisition/award (likely part of compensation or a grant) rather than an open-market purchase or option exercise. Such awards are common for executives; they reflect receipt of company stock but do not by themselves indicate a purchase motivated by a view on the stock. The dollar amount here (~$14.5k) is relatively small for an executive-level award.

Insider Transaction Report

Form 4
Period: 2026-06-05
JORDEN DAVID EMERSON
DirectorCEO/CFO
Transactions
  • Award

    Common Stock

    [F1]
    2026-06-05$1.10/sh+13,245$14,5062,085,000 total
Footnotes (1)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.042 to $1.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.
Signature
/s/ David Jorden|2026-06-05

Documents

1 file
  • 4
    rdgdoc.xmlPrimary

    FORM 4